CTOs on the Move

Clinaero

www.clinaero.com

 
Clinaero is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.clinaero.com
  • 10900 NE 8th St Ste 1260
    Bellevue, WA USA 98004
  • Phone: 425.452.1344

Executives

Name Title Contact Details

Similar Companies

Gaiam, Inc.

Gaiam, Inc. (Gaiam) is a lifestyle media company providing a selection of information, media, products and services to customers, who value personal development, wellness, ecological lifestyles, responsible media and conscious community.

Freedom Designs

Freedom Designs is a Simi Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soka Services

Soka Services LLC is a Pontiac, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Equian

One of our nation’s most pressing challenges is the rising cost and affordability of healthcare. At Equian, our efforts are dedicated to addressing this challenge. We provide solutions that ensure each healthcare interaction is paid accurately and at the lowest possible cost. We have a proven system to reduce healthcare cost through proprietary data analytics coupled with deep domain expertise. Once we have aligned with you and analyzed all of the data, we provide integrated payment integrity solutions that eliminate unnecessary spending.

BioSig Technologies

BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.